International Stem Cell Corp. (ISCO) Enters Agreement with $1 Billion Global Pharmaceutical Company
International Stem Cell Corp., a biotech company developing novel stem cell-based therapies, announced this morning that it has entered into a twelve-month research agreement with Rohto Pharmaceutical Co., Ltd., a global Japanese pharmaceutical company that develops new technology for the medical and cosmetics markets with approximately $1.3 billion in consolidated annual sales. Founded in 1899, Rohto today has products available in more than 150 countries. Rohto has agreed to evaluate stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. If the research is successful and the parties agree on remaining terms, it is…